Skip to main content
Premium Trial:

Request an Annual Quote

Eurofins Medigenomix Licenses Amplification Technology from Orion Diagnostica

NEW YORK (GenomeWeb News) – Eurofins Mediogenomix has licensed co-exclusive rights to Orion Diagnostica's strand invasion-based amplification (SIBA) technology, the firms announced today.

Espoo, Finland-based Orion Diagnostica owns the global rights for the SIBA isothermal nucleic acid detection technology in all fields, the partners noted. Financial and other terms of the agreement were not disclosed.

"The SIBA technology and the associated expertise of Orion Diagnostica are an excellent fit for Eurofins," Peter Persigehl, managing director of Eurofins Medigenomix, which is part of the Eurofins Scientific group. "The cooperation will allow us to broaden Eurofins' portfolio with innovative analytical solutions particularly in the area of DNA-based authenticity testing for food and related products."

The SIBA technology relies on the recombinase-dependent invasion of an oligonucleotide into the target nucleic acid, leading to dissociation of the double-stranded nucleic acid. This enables specific primers to amplify the target exponentially by the action of the polymerase, according to Orion.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.